251 related articles for article (PubMed ID: 32841307)
1. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
[TBL] [Abstract][Full Text] [Related]
3. Relevance of
Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
5. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.
Hernaez R; McLean J; Lazo M; Brancati FL; Hirschhorn JN; Borecki IB; Harris TB; ; Nguyen T; Kamel IR; Bonekamp S; Eberhardt MS; Clark JM; Kao WH; Speliotes EK
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1183-1190.e2. PubMed ID: 23416328
[TBL] [Abstract][Full Text] [Related]
6. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.
Larrieta-Carrasco E; Flores YN; Macías-Kauffer LR; Ramírez-Palacios P; Quiterio M; Ramírez-Salazar EG; León-Mimila P; Rivera-Paredez B; Cabrera-Álvarez G; Canizales-Quinteros S; Zhang ZF; López-Pérez TV; Salmerón J; Velázquez-Cruz R
Exp Mol Pathol; 2018 Feb; 104(1):50-58. PubMed ID: 29307798
[TBL] [Abstract][Full Text] [Related]
8. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.
León-Mimila P; Vega-Badillo J; Gutiérrez-Vidal R; Villamil-Ramírez H; Villareal-Molina T; Larrieta-Carrasco E; López-Contreras BE; Kauffer LR; Maldonado-Pintado DG; Méndez-Sánchez N; Tovar AR; Hernández-Pando R; Velázquez-Cruz R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
Exp Mol Pathol; 2015 Apr; 98(2):178-83. PubMed ID: 25597287
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Lin YC; Chang PF; Chang MH; Ni YH
Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
[TBL] [Abstract][Full Text] [Related]
10. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.
Flores YN; Velázquez-Cruz R; Ramírez P; Bañuelos M; Zhang ZF; Yee HF; Chang SC; Canizales-Quinteros S; Quiterio M; Cabrera-Alvarez G; Patiño N; Salmerón J
Mol Biol Rep; 2016 Dec; 43(12):1359-1369. PubMed ID: 27752939
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
[TBL] [Abstract][Full Text] [Related]
12. American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults.
Kallwitz ER; Tayo BO; Kuniholm MH; Cai J; Daviglus M; Cooper RS; Cotler SJ
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2301-2309. PubMed ID: 30743004
[TBL] [Abstract][Full Text] [Related]
13. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
[TBL] [Abstract][Full Text] [Related]
14. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
[TBL] [Abstract][Full Text] [Related]
15. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
Kitamoto A; Kitamoto T; Nakamura T; Ogawa Y; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Nakao K; Sekine A; Chayama K; Nakajima A; Hotta K
Endocr J; 2014; 61(7):683-9. PubMed ID: 24785259
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
[TBL] [Abstract][Full Text] [Related]
17. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
18. Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan.
Raja AM; Ciociola E; Ahmad IN; Dar FS; Naqvi SMS; Moaeen-Ud-Din M; Kaukab Raja G; Romeo S; Mancina RM
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443539
[TBL] [Abstract][Full Text] [Related]
19. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent.
Palmer ND; Musani SK; Yerges-Armstrong LM; Feitosa MF; Bielak LF; Hernaez R; Kahali B; Carr JJ; Harris TB; Jhun MA; Kardia SL; Langefeld CD; Mosley TH; Norris JM; Smith AV; Taylor HA; Wagenknecht LE; Liu J; Borecki IB; Peyser PA; Speliotes EK
Hepatology; 2013 Sep; 58(3):966-75. PubMed ID: 23564467
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]